Advaxis Inc. (NASDAQ:ADXS) shares were down 4.1% during trading on Wednesday . The stock traded as low as $15.02 and last traded at $15.33, with a volume of 1,073,023 shares traded. The stock had previously closed at $15.98.

Several research analysts recently commented on ADXS shares. HC Wainwright reiterated a “buy” rating and issued a $23.00 price target on shares of Advaxis in a research report on Friday, August 5th. Jefferies Group reiterated a “buy” rating on shares of Advaxis in a research report on Thursday, August 4th. FBR & Co reiterated an “outperform” rating and issued a $34.00 price target on shares of Advaxis in a research report on Tuesday, May 17th. Finally, Barclays PLC lifted their price target on Advaxis from $15.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 3rd. Six research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of $25.80.

The stock’s 50-day moving average is $9.13 and its 200 day moving average is $8.27. The firm’s market capitalization is $508.32 million.

In other news, Director Thomas J. Mckearn sold 4,100 shares of the stock in a transaction that occurred on Friday, May 13th. The stock was sold at an average price of $7.45, for a total value of $30,545.00. Following the completion of the transaction, the director now owns 82,120 shares of the company’s stock, valued at approximately $611,794. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.